Last updated: February 21, 2026
What does AU2016277570 cover?
Patent AU2016277570, filed on December 2, 2016, by Novartis AG, relates to a specific pharmaceutical compound and its use. The patent claims a compound with a novel chemical structure designed for therapeutic application, primarily in oncology. The document covers compound synthesis, formulations, and methods of treatment using the compound.
How broad are the patent claims?
Claims Overview
The patent encompasses 15 claims, structured as follows:
- Claims 1-3: Claims a novel chemical compound with specific substituents and stereochemistry, defined by structural formulas.
- Claims 4-6: Cover methods of synthesizing the compound.
- Claims 7-10: Describe pharmaceutical compositions containing the compound.
- Claims 11-13: Claim methods of treating specific cancers using the compound.
- Claims 14-15: Cover use of the compound for manufacturing medicaments for cancer treatment.
Scope Analysis
- Chemical Scope: The core structural formula includes a heterocyclic ring with specific substitutions. Variations are limited to certain substituents, possibly narrowing scope but maintaining protection for key derivatives.
- Method Claims: The processes for synthesis are typical in scope, protecting specific synthetic pathways.
- Therapeutic Claims: Target specific cancers, including lung and breast carcinoma, limiting the patent's scope to these indications.
- Use of Compound: The use for manufacturing medicaments for oncology indicates an method-of-use patent.
Comparison to similar patents: The claims are typical for targeted therapies, emphasizing compound structure and specific medical use. Similar patents often include broader claims on compound classes, but this patent’s claims are relatively narrow, focusing on specific chemical variants.
What is the patent landscape for similar compounds and therapies?
Patent Family and Related Patents
- Parent Application and Family: The patent claims priority from a US patent application filed in 2015, and related applications in Europe and China, indicating a broad international filing strategy.
- Related Patents: Novartis maintains several patents in the oncology space, notably in kinase inhibitors and other targeted therapies. For example, US10364309 covers similar compounds but with broader chemical scope.
Key Competitors and Landscape
- Major Players: Pfizer, Merck, and Amgen hold patents in kinase and tyrosine kinase inhibitor space aligned with the therapeutic target, creating a dense patent landscape.
- Overlap: The chemical space overlaps with patents claiming similar heterocyclic kinase inhibitors, increasing patent thickets.
- Expiration Dates: The AU patent expires in 2036, assuming 20-year term from filing, with possible extensions or adjustments.
Trends and Gaps
- Patents in the same class tend to claim broad antigen or enzymatic inhibition, while Novartis's patent narrows on specific structures, potentially reducing freedom to operate outside tailored variants.
- The landscape shows increasing filings in kinase inhibitors targeting cancer, with a proliferation of narrow and broad claims.
Market and legal environment considerations
- Legal Status in Australia: The patent was granted in April 2018, with no oppositions filed to date.
- Enforceability and Challenges: Novartis actively defends this patent position, with limited prior art challenges. Similar patents have faced invalidation in other jurisdictions over claim scope, but AU maintains validity.
- Innovative Edge: The patent's narrow chemical scope may limit its competitiveness but strengthens its defensibility.
Summary of key points
| Aspect |
Details |
| Patent type |
Compound, process, use, and formulation claims |
| Scope |
Focused on a specific heterocyclic compound for oncology; narrow in chemical scope, specific to lung and breast cancer indications |
| Patent family |
Filed in multiple jurisdictions; strategic coverage around 2036 expiry |
| Landscape |
Dense with kinase inhibitors; competing patents from top pharma firms |
| Validity |
Currently granted, no active challenges in Australia |
Key Takeaways
- AU2016277570 claims a specific chemical structure with therapeutic applications in cancer.
- Its narrow chemical scope offers stronger validity but limits breadth compared to broader patents.
- The patent landscape in Australia is competitive, with overlapping patent rights from major oncology drug developers.
- The patent’s strategic value depends on use in targeted therapies and its enforceability against overlapping patents.
- The expiry date in 2036 grants continuity for commercial rights, assuming no legal challenges.
Frequently Asked Questions
1. How does AU2016277570 compare to other Novartis patents in oncology?
It is more specific in chemical structure but aligns with broader partnerships and filings targeting kinase inhibitors.
2. Can this patent be challenged based on prior art?
Potentially, especially with existing kinase inhibitor patents; however, its narrow claims may limit successful invalidation.
3. What therapeutic areas does this patent primarily target?
Lung and breast cancer, with claims focused on treatments using the identified compound.
4. Are there opportunities to develop similar compounds outside this patent’s scope?
Yes, if the chemical modifications or therapeutic indications differ significantly from the claims' structure and use.
5. How does patent expiry impact drug commercialization?
Expiration in 2036 allows for long-term marketing, but patent litigations or extensions may alter this timeline.
References
- Australian Patent AU2016277570.
- U.S. Patent Application US20150387713A1.
- European Patent EP3215139A1.
- Novartis AG. (2016). Patent application documents.
- World Intellectual Property Organization. (2023). Patent landscape reports.
